ClinicalTrials.gg
CompletedNCT02162485Updated Sep 29, 2015

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

A Phase 1 interventional study of Salmeterol/fluticasone Easyhaler and Salmeterol/fluticasone Easyhaler with charcoal in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-29.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
6th of 19
129 · median 72
Started
2014
with 1 other
Phase 1
12 of 21
none open now
Registered
13th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2014, is one of 12 in phase 1, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The purposes of this study is to compare the test products Salmeterol/fluticasone Easyhaler with marketed product Seretide Diskus in terms of the drug absorbed into the blood stream

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained
  • Good general health ascertained by detailed medical history, and laboratory and physical examinations

Exclusion criteria

Exclusion Criteria:

  • Evidence of a cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease within the previous 2 years
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. As an exception, paracetamol and ibuprofen for occasional pain are allowed
  • Known to the active substance(s) or the (lactose, which contains small amounts of milk protein) of the drug
  • Pregnant or lactating females
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Salmeterol/fluticasone Easyhaler

    Single dose of Salmeterol/fluticasone Easyhaler

    Drug: Salmeterol/fluticasone Easyhaler

  • Experimental
    Salmeterol/fluticasone Easyhaler with charcoal

    Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)

    Drug: Salmeterol/fluticasone Easyhaler with charcoal

  • Active comparator
    Seretide Diskus

    Single dose of Seretide Diskus

    Drug: Seretide Diskus

  • Active comparator
    Seretide Diskus with charcoal

    Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)

    Drug: Seretide Diskus with charcoal

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of plasma salmeterol and fluticasone propionate

    Time frame: within 34 h

  2. AUCt of plasma salmeterol and fluticasone propionate

    Time frame: 34 h

07

Study locations

1 site
  • Orion Pharma Pharmacology Unit
    Espoo, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2014
First posted
Jun 12, 2014
Start
Jun 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Sep 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02162485
Responsible party
Sponsor
First posted
Jun 12, 2014
Start date
Jun 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Sep 29, 2015

Study contacts

Merja Mäkitalo
study director · Orion Corporation, Orion Pharma
Leena Mattila, MD, PhD
principal investigator · Orion Pharma Clinical Pharmacology Unit, Espoo, Finland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion